Oppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00

Keros Therapeutics (NASDAQ:KROSFree Report) had its price objective lowered by Oppenheimer from $102.00 to $63.00 in a research report report published on Monday morning, Marketbeat Ratings reports. The firm currently has an outperform rating on the stock.

KROS has been the subject of a number of other reports. Bank of America cut their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. HC Wainwright decreased their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday. Finally, Wedbush restated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $81.33.

Check Out Our Latest Stock Analysis on KROS

Keros Therapeutics Trading Up 3.1 %

KROS opened at $19.42 on Monday. The firm has a market capitalization of $786.65 million, a PE ratio of -3.73 and a beta of 1.20. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The firm’s 50-day moving average price is $58.29 and its 200 day moving average price is $52.50.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the company posted ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. As a group, analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. Charles Schwab Investment Management Inc. grew its holdings in shares of Keros Therapeutics by 14.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics during the 2nd quarter worth approximately $1,118,000. Intech Investment Management LLC acquired a new stake in Keros Therapeutics during the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp boosted its position in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after buying an additional 18,755 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Featured Articles

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.